HOME >> MEDICINE >> NEWS
MRI superior to ultrasound in predicting cerebral palsy in preterm infants

In a comparison study between MRI and ultrasound for predicting cerebral palsy in very low birth weight (VLBW) infants, researchers from Stanford University Medical Center in Palo Alto, CA, found that MRI is superior to ultrasound in both sensitivity and positive predictive value for cerebral palsy, whereas both ultrasound and MRI showed relatively high specificity and negative predictive value.

Based on the results of the study, the authors recommend that ultrasound screening be performed for all VLBW infants, including at near-term. If ultrasound is predictive of cerebral palsy, then MRI may not be needed. If ultrasound is not predictive of cerebral palsy, MRI with diffusion tensor imaging should be performed. Pat Barnes, MD, one of the authors of the study, explained, "Since ultrasound is more readily available (including its portability in the intensive care setting) and less expensive, it is used first. If it shows findings predictive of cerebral palsy, then there is probably no need for MRI. If conventional MRI is needed, then diffusion tensor imaging is done at that time and would be important to do especially if the conventional MRI is negative or nonspecific."

According to the authors, other indications could also influence the choice of imaging technique used. "For managing the acutely ill preterm newborn, especially for intraventricular hemorrhage and posthemorrhagic hydrocephalus, ultrasound is indicated. If there are other or additional concerns (for example, white matter injury), then MRI with diffusion tensor imaging is clearly superior," said Dr. Barnes.

The researchers are currently investigating the role of MR spectroscopy in predicting cerebral palsy in VLBW infants. According to Dr. Barnes, "We are now just collecting that data. The potential is that MR spectroscopy may detect metabolic changes when no macrostructural changes (by ultrasound or conventional MRI) or microstructural changes (by diffusion tensor imaging) are
'"/>

Contact: Jason Ocker
jason@arrs.org
703-858-4304
American Roentgen Ray Society
3-May-2004


Page: 1 2

Related medicine news :

1. Kinder, gentler procedure gives superior results for stem cell transplants
2. Therapy, medication combination superior for children with obsessive-compulsive disorder
3. Universit de Montral study shows superior sound-location skills in the blind
4. CellCept(R) registry data demonstrated superior long-term organ transplant outcomes
5. Wavefront LASIK demonstrated superior to conventional LASIK
6. Transvaginal ultrasound superior to transrectal ultrasound for staging rectal cancer in women
7. Mycophenolate mofetil superior to azathioprine: Slows vascular disease progression after transplant
8. Linezolid is superior treatment for drug-resistant pneumonia
9. PET scans superior in revealing response to treatment for gastrointestinal stromal tumors
10. Endovascular coil superior to neurosurgery for treatment of brain haemorrhage
11. Secret agents secret revealed - shaken martinis have superior antioxidant properties to those that are stirred

Post Your Comments:
(Date:3/2/2015)... March 02, 2015 Over the last ... among leading vendors seeking to expand their geographic presence ... is expected to reach $6.2 billion by 2019 at ... America including the U.S. and Canada and a major ... However developing regions such as Asia-Pacific including China and ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... 02, 2015 LegitScript, LLC, ... certification programs, including those for Internet pharmacy ... safety and classification, has launched a certification ... The new program, called iCareRx , ... regarding the identity of the owner/operator of ...
(Date:3/2/2015)... Atlantic Information Services, Inc. (AIS) is pleased to ... Plans: 2015 , the all-new 12th edition of the ... market, with enrollment data and contact information for health ... as a printed book containing the full directory and ... and charts, as well as an electronic version, AIS’s ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Regulatory ... focused on quality, regulatory and technical consulting, announces ... Chief Operating Officer. , Before joining RCA, ... leading R&D teams in all aspects of developing ... positions at Covidien (Medtronic), Regulatory Compliance Associates Inc., ...
Breaking Medicine News(10 mins):Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Therapeutic Ultrasound Devices Market worth $6.2 Billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2
(Date:3/2/2015)... 2015  DURECT Corporation (Nasdaq: DRRX ... the successful completion of a Phase 1 clinical ... DUR-928 is an endogenous, small-molecule, new chemical entity ... diseases such as nonalcoholic fatty liver disease (NAFLD) ... injuries such as acute kidney injury (AKI).        ...
(Date:3/2/2015)... 2, 2015  Intrexon Corporation (NYSE: ... announced its fourth quarter and full year results ... Recent Developments: , Acquired ActoGeniX, a European ... in cellular therapeutics and other innovative products.  Its ... food-grade microbes ( Lactococcus lactis ) to generate ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 2Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 3Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 4Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 5Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 6Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 7Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 8Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 9Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 10Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 11Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 12Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 13Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 14Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 16Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 17Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 18Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 19Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 20Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 21Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 22Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 23Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results 24Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
Cached News: